| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Y-39983 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | -0.18 | 0.2 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.065 | 0.2 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.2 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |